Park Eun-Jin, Lee Sangku, Jeong Tae-Sook, Bok Song-Hae, Lee Mi-Kyung, Park Yong Bok, Choi Myung-Sook
Department of Food Science and Nutrition, Kyungpook National University, 702-701 Daegu, Korea.
J Biochem Mol Toxicol. 2004;18(5):279-87. doi: 10.1002/jbt.20036.
The effect of 3,4-di(OH)-phenylpropionic acid (L-phenylalanine methyl ester) amide (SL-1063), a synthetic derivative of 3,4-di(OH)-cinnamate, on the cholesterol metabolism and antioxidant enzyme system was examined in rats. Diets that included either SL-1063 (0.046%, w/w) or lovastatin (0.02%, w/w) as a supplement, plus 1 g cholesterol/100 g diet were fed to rats ad libitum for 5 weeks. The total plasma cholesterol and triglyceride levels were significantly lowered by the SL-1063 supplement compared to the control group. Meanwhile, the levels of plasma HDL-cholesterol and ratio of HDL-cholesterol/total cholesterol (%) were significantly higher in the SL-1063 group than in the control group. However, the lovastatin supplement did not affect the plasma lipid level. The hepatic cholesterol level and 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) reductase activity were significantly lowered in the lovastatin group compared to the SL-1063 group; however, the hepatic triglyceride level did not differ among the groups. The activity of hepatic acyl CoA: cholesterol acyltransferase (ACAT), the enzyme that catalyzes hepatic cholesterol esterification, was significantly lower in the lovastatin and SL-1063 groups than in the control group. Furthermore, the SL-1063 supplement elevated the excretion of fecal sterols. As regards the hepatic antioxidant enzyme system, the superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (GSH-Px), and glutathione reductase (GR) activities were all significantly higher in the SL-1063 group compared to the control group, whereas only the GR activity was significantly increased by the lovastatin supplement. No marked difference in the GSH levels and glucose-6-phosphate dehydrogenase (G6PD) activities was observed among the groups. The levels of plasma and hepatic thiobarbituric acid reactive substances (TBARS) were lowered by the SL-1063 supplement compared to the control group. Accordingly, the current results suggest that SL-1063, a synthetic derivative of 3,4-di(OH)-cinnamate, is effective in lowering the plasma lipids and improving the antioxidant enzyme system.
在大鼠中研究了3,4 - 二（羟基） - 苯丙酸（L - 苯丙氨酸甲酯）酰胺（SL - 1063），一种3,4 - 二（羟基）肉桂酸的合成衍生物，对胆固醇代谢和抗氧化酶系统的影响。将含有SL - 1063（0.046%，w/w）或洛伐他汀（0.02%，w/w）作为补充剂，外加1 g胆固醇/100 g饲料的饮食随意喂给大鼠5周。与对照组相比，SL - 1063补充剂显著降低了血浆总胆固醇和甘油三酯水平。同时，SL - 1063组的血浆高密度脂蛋白胆固醇水平和高密度脂蛋白胆固醇/总胆固醇（%）比值显著高于对照组。然而，洛伐他汀补充剂对血浆脂质水平没有影响。与SL - 1063组相比，洛伐他汀组的肝脏胆固醇水平和3 - 羟基 - 3 - 甲基戊二酰辅酶A（HMG - CoA）还原酶活性显著降低；然而，各组之间的肝脏甘油三酯水平没有差异。催化肝脏胆固醇酯化的酶——肝脏酰基辅酶A：胆固醇酰基转移酶（ACAT）的活性在洛伐他汀组和SL - 1063组中显著低于对照组。此外，SL - 1063补充剂增加了粪便固醇的排泄。关于肝脏抗氧化酶系统，与对照组相比，SL - 1063组的超氧化物歧化酶（SOD）、过氧化氢酶（CAT）、谷胱甘肽过氧化物酶（GSH - Px）和谷胱甘肽还原酶（GR）活性均显著更高，而洛伐他汀补充剂仅显著增加了GR活性。各组之间谷胱甘肽（GSH）水平和葡萄糖 - 6 - 磷酸脱氢酶（G6PD）活性没有明显差异。与对照组相比，SL - 1063补充剂降低了血浆和肝脏中硫代巴比妥酸反应性物质（TBARS）的水平。因此，目前的结果表明，3,4 - 二（羟基）肉桂酸的合成衍生物SL - 1063在降低血浆脂质和改善抗氧化酶系统方面是有效的。
